Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor
US7671056B2 · kind B2 · utility
0Cited by
21References
67Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 2006 |
| Grant date | Mar 2, 2010 |
| Priority date | — |
| Expiry date | Mar 16, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction. The invention relates to compounds and pharmaceutically acceptable salts of formula (I′):wherein R1-R16, Ra, Rb, and n are set forth in the specification. The invention also relates to pharmaceutical compositions comprising compounds and pharmaceutically acceptable salts of formula (I′).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.